NDA 204441 · Otsuka
Jynarque
Tolvaptan · Oral · Vasopressin V2 Receptor Antagonist
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Apr 23, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
104
40 Phase 3, 3 recruiting
FAERS reports
8,701
6,653 serious, 1,432 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS LIVER INJURY JYNARQUE (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported [see Warnings and Precautions (5.1) ] . Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter [see Warnings and Precautions (5.1) ] . Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity. Because of the risks of serious liver injury, JYNARQUE is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Tolvaptan for ADPKD Shared System REMS [see Warnings and Precautions (5.2) ] . WARNING: RISK OF SERIOUS LIVER...
What it is approved for
From the label in effect Sep 30, 2026.
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is a selective vasopressin V 2 -receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) ( 1 )
Mechanism: Tolvaptan is a selective vasopressin V 2 -receptor antagonist with an affinity for the V 2 -receptor that is 1.8 times that of native arginine vasopressin (AVP). Tolvaptan affinity for the V 2 -receptor is 29 times that for the V 1a -receptor. Decreased binding of vasopressin to the V 2 -receptor in the kidney lowers adenylate cyclase activity resulting in a decrease in intracellular adenosine 3′, 5′-cyclic monophosphate (cAMP) concentrations. Decreased cAMP concentrations prevent aquaporin 2 containing vesicles from fusing with the plasma membrane, which in turn causes an increase in urine...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2018 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelOrphanLetterReviewLabel
5 products under this application
- JYNARQUE · TOLVAPTAN 45MG · TABLET, ORAL · Prescription · TE AB2
- JYNARQUE · TOLVAPTAN 15MG · TABLET, ORAL · Prescription · TE AB2
- JYNARQUE · TOLVAPTAN 60MG · TABLET, ORAL · Prescription · TE AB2
- JYNARQUE · TOLVAPTAN 30MG · TABLET, ORAL · Prescription · TE AB2
- JYNARQUE · TOLVAPTAN 90MG · TABLET, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Tolvaptan" as an intervention, any sponsor and status, largest first.
- EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With TolvaptanPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00071331 · 3,600 participants · Start Sep 2003 · Primary completion Jul 2006
Drug: Tolvaptan · For: Congestive Heart Failure
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 378 sites in all
- Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseasePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02251275 · 1,803 participants · Start Oct 17, 2014 · Primary completion Nov 9, 2018
Drug: Tolvaptan · For: Polycystic Kidney, Autosomal Dominant
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 210 sites in all
- Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00428948 · 1,445 participants · Start Jan 2007 · Primary completion Jan 2012
Drug: Tolvaptan; Placebo · For: Polycystic Kidney Disease, Autosomal Dominant
Sites: Mobile, Alabama; Riverside, California; Stanford, California · 133 sites in all
- Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseasePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02160145 · 1,370 participants · Start May 2014 · Primary completion Apr 18, 2017
Drug: Tolvaptan (OPC-41061); Placebo · For: Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 230 sites in all
- Tolvaptan Extension Study in Participants With ADPKDPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01214421 · 1,083 participants · Start May 26, 2010 · Primary completion Feb 29, 2016
Drug: Tolvaptan · For: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sites: Mobile, Alabama; Peoria, Arizona; Tempe, Arizona · 97 sites in all
- Phase III Study of Tolvaptan Tablet to Treat Cirrhosis AscitesPivotal-lookingCompleted
Otsuka Beijing Research InstituteOtsuka
NCT01349348 · 535 participants · Start Oct 2010 · Primary completion May 2012
Drug: Tolvaptan; Tolvaptan and 1 more · For: Ascites; Hepatic Cirrhosis
Sites: Shanghai, China
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of LifePivotal-lookingRecruiting
University Medical Center GroningenAcademic, hospital or other
NCT05373264 · 300 participants (planned) · Start Jul 31, 2024 · Primary completion Jul 2030
Drug: Hydrochlorothiazide 25 mg; Placebo · For: ADPKD
Sites: Graz, Austria; Innsbruck, Austria; Antwerp, Belgium · 25 sites in all
- Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart FailurePivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT03772041 · 294 participants · Start Jan 16, 2019 · Primary completion Jul 21, 2020
Drug: OPC-61815; Tolvaptan Tab 15 MG · For: Congestive Heart Failure
Sites: Kumamoto, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- thirst907
- product dose omission issue749
- death586
- pollakiuria586
- renal impairment529
- polyuria419
- no adverse event408
- wrong technique in product usage process407
- fatigue393
- inappropriate schedule of product administration369
- underdose361
- blood creatinine increased345
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 28 |
| 2013 | 33 |
| 2014 | 42 |
| 2015 | 254 |
| 2016 | 219 |
| 2017 | 238 |
| 2018 | 370 |
| 2019 | 478 |
| 2020 | 308 |
| 2021 | 407 |
| 2022 | 602 |
| 2023 | 796 |
| 2024 | 1,345 |
| 2025 | 1,929 |
| 2026 | 1,643 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jynarque (Tolvaptan)
2024 spending
$103M
Beneficiaries
585
5,415 claims
Per beneficiary
$176,885
$346.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,490,637 |
| 2021 | $46,234,050 |
| 2022 | $60,705,731 |
| 2023 | $76,164,444 |
| 2024 | $103,477,556 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Multicenter Study
- Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials.
Cannatà A, Anastasia G, De Marzo V, et al. · Eur Heart J Cardiovasc Pharmacother 2026 · Systematic Review, Meta-Analysis
- Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, et al. · Clin J Am Soc Nephrol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
St Pierre K, Cashmore BA, Bolignano D, et al. · Cochrane Database Syst Rev 2024 · Systematic Review
- Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.
Cox ZL, Hung R, Lenihan DJ, et al. · JACC Heart Fail 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.